Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Stiff

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Research Square|June 22, 2026
Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 resultsNirav Shah, Hannah Choe, Nancy Hardy, et al.
Transplantation and Cellular Therapy|July 5, 2021
A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic MalignanciesWael Saber, Patricia Steinert, Mei-Jie Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemiaOlatoyosi M Odenike, Serhan Alkan, Dorie Sher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphomaHenry C Fung, Patrick Stiff, Jeff Schriber, et al.
Haematologica|September 17, 2016
Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in miceJunping Xin, Peter Breslin, Wei Wei, et al.
Blood|September 30, 2018
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H Moskowitz, Jan Walewski, Auayporn Nademanee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2012
TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomesSung W Choi, Patrick Stiff, Kenneth Cooke, et al.
British Journal of Haematology|September 22, 2016
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphomaScott D Ramsey, Auayporn Nademanee, Tamas Masszi, et al.
The New England Journal of Medicine|December 17, 2004
Palifermin for oral mucositis after intensive therapy for hematologic cancersRicardo Spielberger, Patrick Stiff, William Bensinger, et al.
Transplantation and Cellular Therapy|April 29, 2023
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 SubstudyPaul Szabolcs, Roei D Mazor, Dima Yackoubov, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Research Square|June 22, 2026
Itacitinib plus calcineurin inhibitor-based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 resultsNirav Shah, Hannah Choe, Nancy Hardy, et al.
Transplantation and Cellular Therapy|July 5, 2021
A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic MalignanciesWael Saber, Patricia Steinert, Mei-Jie Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemiaOlatoyosi M Odenike, Serhan Alkan, Dorie Sher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphomaHenry C Fung, Patrick Stiff, Jeff Schriber, et al.
Haematologica|September 17, 2016
Necroptosis in spontaneously-mutated hematopoietic cells induces autoimmune bone marrow failure in miceJunping Xin, Peter Breslin, Wei Wei, et al.
Blood|September 30, 2018
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCraig H Moskowitz, Jan Walewski, Auayporn Nademanee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2012
TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomesSung W Choi, Patrick Stiff, Kenneth Cooke, et al.
British Journal of Haematology|September 22, 2016
Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphomaScott D Ramsey, Auayporn Nademanee, Tamas Masszi, et al.
The New England Journal of Medicine|December 17, 2004
Palifermin for oral mucositis after intensive therapy for hematologic cancersRicardo Spielberger, Patrick Stiff, William Bensinger, et al.
Transplantation and Cellular Therapy|April 29, 2023
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 SubstudyPaul Szabolcs, Roei D Mazor, Dima Yackoubov, et al.
Pageof 6